Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO

Richard Drury Telix Pharmaceuticals Limited ( NASDAQ: TLX ) is a relatively large Australian company that was recently IPO-ed in the U.S. It has a diverse pipeline and multiple commercial products, but information is scarce, TLX being a foreign issuer.

There is no Annual About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.



Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

Total Pharma Tracker Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).

I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.

Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

.